ACA opponents have another set of tools to use in a future White House with different policy goals than further doses of Obamacare.
Advances in medical device technology have been major contributors to improved longevity and increased quality of life for patients. Unfortunately, damaging “conflict-of-interest myths” are hampering medical progress in general and device development in particular.
If we’re truly honest about seeking greater value in how drugs are pursued and used, then we should be earnest in wanting a market with more information that speaks to these attributes, and more competition in pursuit of these elements.
Disappointed critics of Obamacare should become both more patient and persistent. Some change, and better health-care policy, is ahead.
Brill explains how federally sanctioned state Medicaid provider taxes operate and affect federal Medicaid spending. He proposes that Congress prohibit these taxes and either put the federal savings back into Medicaid or use them to reduce federal healthcare taxes.
Both of Thursday’s Supreme Court decisions were victories for the Obama administration and for the proposition that the executive branch can rewrite laws to say what they want them to say.
Before we hold a going-out-of-business sale for the rule of law, following yesterday’s King v. Burwell ruling at the Supreme Court, let’s review some between-the-lines highlights. The Scalia dissent already took care of the fundamental analysis of how the Court veered so far off course.
Our mission now: ensure precision medicine delivers more smiles – and more hours.
After this decision there is little left to distinguish the state and federal exchanges.
A discussion on Obamacare and the fallout from the King v. Burwell Supreme Court ruling.